Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Healthy aging is the broadest outcome category for Urolithin A research, encompassing muscle function, mitochondrial health, immune function, and inflammatory biomarkers. This page provides a cross-cutting summary of what clinical trials show about Urolithin A's potential role in age-related decline — with clear boundaries between what has been demonstrated and what remains speculative. The scientific rationale for studying UA in aging is based on mitochondrial dysfunction being recognized as one of the 12 hallmarks of aging. However, 'healthy aging' is not a single measurable endpoint — it is an umbrella concept that requires evidence across multiple domains.
Your Doctor Won't Tell You This About Cellular Energy
Not because they don't care — because they weren't trained in mitochondrial science. But the research is clear.
Detailed Evidence
DOMAIN 1: MUSCLE FUNCTION & PHYSICAL PERFORMANCE The strongest clinical evidence links UA to improved muscle endurance and strength in older and middle-aged adults. The Liu 2022 JAMA trial (n=66, ages 65–90) showed 12–17% improvements in muscle endurance measures over 4 months. The Singh 2022 trial (n=88, ages 40–64) confirmed leg strength and VO₂max improvements. These functional outcomes are directly relevant to healthy aging, as age-related muscle decline (sarcopenia) is a major contributor to disability in older adults. DOMAIN 2: MITOCHONDRIAL BIOMARKERS All human trials consistently show improvements in plasma acylcarnitine profiles and other mitochondrial biomarkers. These changes suggest improved mitochondrial function at the systemic level. The 28-day Andreux 2019 trial showed dose-dependent biomarker changes, confirmed in subsequent 4-month trials. DOMAIN 3: IMMUNE FUNCTION A 2025 randomized, placebo-controlled trial published in Nature Aging directly examined UA's effects on age-related immune decline (immunosenescence). The trial reported improvements in certain immune cell populations and reductions in age-associated inflammatory markers in older adults. This is a single trial and represents early-stage evidence, but it suggests potential immunomodulatory effects relevant to aging. DOMAIN 4: INFLAMMATION Multiple trials report decreases in C-reactive protein (CRP) and inflammatory cytokines (IL-6, TNF-α) as secondary endpoints. Chronic low-grade inflammation ('inflammaging') is recognized as a driver of age-related diseases. CRP decreased ~30% vs placebo in the JAMA trial. The Zhu 2024 athlete study also showed inflammatory marker reductions. DOMAIN 5: CARDIOVASCULAR BIOMARKERS (EMERGING) The Denk 2025 Nature Communications study provided preclinical cardioprotective evidence with a sub-analysis of human cardiovascular biomarkers showing improvement. Cardiovascular disease is the leading cause of death in aging populations, making this a relevant but early-stage area. CROSS-CUTTING EVIDENCE ASSESSMENT The healthy aging evidence for Urolithin A is promising but incomplete. Strong evidence exists for muscle endurance biomarkers; moderate evidence for mitochondrial and inflammatory markers; and emerging evidence for immune function and cardiovascular outcomes. No trials have measured hard aging endpoints such as disease incidence, disability-free years, or mortality.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
The Cellular Renewal Protocol That Works While You Sleep
Your body does its deepest repair work at night. Give it the raw materials to rebuild stronger, healthier cells by morning.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Does Urolithin A slow aging?
No human trial has measured aging as an endpoint. UA extended C. elegans lifespan by 45% in preclinical studies, but this should not be extrapolated to humans. Evidence shows improvements in age-related biomarkers (muscle, mitochondrial, inflammatory).
What aspects of aging does Urolithin A target?
Five domains: muscle function (sarcopenia), mitochondrial biomarkers, inflammation (inflammaging), immune function (immunosenescence), and cardiovascular biomarkers (emerging). Strongest evidence is for muscle endurance.
Does Urolithin A improve immune function in older adults?
A 2025 Nature Aging RCT reported improvements in certain immune cell populations and reductions in age-associated inflammatory markers in older adults. This is a single trial representing early-stage evidence requiring replication.
What is immunosenescence and does UA address it?
Immunosenescence is the age-related decline in immune function. The 2025 Nature Aging trial directly examined this, reporting improvements in immune cell populations. This is emerging evidence from a single trial.
Is Urolithin A an anti-aging supplement?
UA targets mechanisms relevant to aging (mitophagy, mitochondrial function). However, "anti-aging" is not a validated clinical endpoint. The evidence supports age-related biomarker improvements, not proven anti-aging effects in humans.
How does Urolithin A compare to other anti-aging interventions?
No head-to-head comparisons with established interventions (exercise, Mediterranean diet, caloric restriction) have been conducted. Exercise remains the most evidence-supported intervention for healthy aging.
What age groups benefit most from Urolithin A?
Both the Liu 2022 (ages 65–90) and Singh 2022 (ages 40–64) trials showed benefits, suggesting relevance across the adult lifespan. The 65–90 group showed the most direct relevance to age-related decline.
Does Urolithin A reduce 'inflammaging'?
CRP decreased ~30% vs placebo in the JAMA trial, and IL-6/TNF-α decreased in the athlete study. Inflammaging (chronic low-grade inflammation) is a recognized driver of age-related diseases, making these findings relevant.
Can Urolithin A prevent age-related diseases?
No trial has measured disease prevention. All trials used biomarker or functional endpoints. Whether UA prevents cardiovascular disease, neurodegeneration, or other age-related diseases is unknown.
Does Urolithin A extend lifespan?
UA extended C. elegans lifespan by 45% in preclinical studies. No human lifespan data exists. Preclinical lifespan results should not be extrapolated to expected human benefits.
What is the role of mitochondria in aging?
Mitochondrial dysfunction is one of the 12 hallmarks of aging (López-Otín et al., Cell, 2023). Declining mitochondrial function drives age-related cellular decline, providing the rationale for mitophagy-activating interventions.
Does Urolithin A improve cardiovascular aging?
The Denk 2025 Nature Communications study showed preclinical cardioprotective effects with a human biomarker sub-analysis showing improvement. This is emerging, early-stage evidence requiring prospective cardiovascular trials.
Is the healthy aging evidence for Urolithin A strong enough to recommend?
The evidence is promising but incomplete. Strong for muscle endurance, moderate for mitochondrial/inflammatory markers, emerging for immune/cardiovascular. No hard aging endpoints measured. Individual decisions should involve a healthcare provider.
Does Urolithin A affect biological age?
No trial has measured biological age markers (epigenetic clocks, telomere length). Evidence is limited to functional and biomarker endpoints. Whether UA affects biological age measurements is unknown.
Should older adults take Urolithin A?
The evidence is most directly relevant to older adults (the JAMA trial enrolled ages 65–90). Decisions should be individualized with a healthcare provider, considering the promising but incomplete evidence base.
Key Research Facts
Clinical trials show 12–17% improvements in muscle endurance measures in older adults (65–90 years) — directly relevant to combating age-related sarcopenia.
Strong EvidenceLiu et al., JAMA Network Open — doi:10.1001/jamanetworkopen.2021.44279
A 2025 Nature Aging RCT reported improvements in immune cell populations in older adults, suggesting Urolithin A may modulate immunosenescence.
Emerging EvidenceNature Aging — doi:10.1038/s43587-025-00996-x
Multiple trials consistently show improvements in plasma acylcarnitine profiles — markers of mitochondrial function — over 28 days to 4 months.
Strong EvidenceAndreux et al., 2019; Singh et al., 2022 — doi:10.1038/s42255-019-0073-4
CRP decreased approximately 30% vs placebo over 4 months — relevant to 'inflammaging,' a recognized driver of age-related diseases.
Moderate EvidenceLiu et al., JAMA Network Open — doi:10.1001/jamanetworkopen.2021.44279
Urolithin A extended C. elegans lifespan by 45%, though preclinical lifespan results should not be extrapolated to expected human benefits.
Strong EvidenceRyu et al., Nature Medicine — doi:10.1038/nm.4132
No trial has measured hard aging endpoints — disease prevention, disability-free years, hospitalization, or mortality.
Strong EvidenceJayatunga et al., Ageing Research Reviews — pubmed:39002645
A 2025 Nature Communications study showed cardioprotective effects with mitochondrial quality enhancement in preclinical models.
Emerging EvidenceDenk et al., Nature Communications — doi:10.1038/s41467-025-57067-3
The healthy aging evidence spans five domains: muscle function, mitochondrial biomarkers, inflammation, immune function, and cardiovascular health.
Moderate EvidenceJayatunga et al., 2024 — pubmed:39002645
Both the Liu 2022 (ages 65–90) and Singh 2022 (ages 40–64) trials showed benefits, suggesting relevance across the adult lifespan.
Strong EvidenceLiu et al., 2022; Singh et al., 2022 — doi:10.1001/jamanetworkopen.2021.44279
The evidence base lacks large-scale longitudinal studies tracking aging outcomes over years — all published trials are 4 months or shorter.
Strong EvidenceJayatunga et al., 2024 — pubmed:39002645
Citations & External Resources
ClinicalTrials.gov — Search: Urolithin A
FDA GRAS Notice GRN 000833 — Urolithin A
EFSA Novel Food Catalogue — Urolithin A
PubMed — Urolithin A research
Nature Medicine — Ryu et al. 2016 (Landmark Study)
JAMA Network Open — Liu et al. 2022 (Muscle Endurance RCT)
Nature Aging — Immune Function Trial 2025
Cell — López-Otín et al. 2023: 12 Hallmarks of Aging
Nature Communications — Denk et al. 2025 (Cardiovascular)
National Institute on Aging — What Is Healthy Aging?
Imagine Waking Up Feeling 10 Years Younger. Now Imagine the Science Behind It.
This isn't wishful thinking. It's cellular biology. Peer-reviewed compounds targeting the actual machinery of aging.
Related Reading
Urolithin A & Mitochondrial Health: Evidence Summary
Urolithin A & Inflammatory Biomarkers: What Studies Report
Urolithin A for Muscle Endurance: What Human Studies Show
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026